Browse RGL1

Summary
SymbolRGL1
Nameral guanine nucleotide dissociation stimulator-like 1
Aliases RGL; ralGDS-like 1
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00788 Ras association (RalGDS/AF-6) domain
PF00617 RasGEF domain
PF00618 RasGEF N-terminal motif
Function

Probable guanine nucleotide exchange factor.

> Gene Ontology
 
Biological Process -
Molecular Function GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0008321 Ral guanyl-nucleotide exchange factor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
Reactome R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1989781: PPARA activates gene expression
R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
Summary
SymbolRGL1
Nameral guanine nucleotide dissociation stimulator-like 1
Aliases RGL; ralGDS-like 1
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RGL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRGL1
Nameral guanine nucleotide dissociation stimulator-like 1
Aliases RGL; ralGDS-like 1
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RGL1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRGL1
Nameral guanine nucleotide dissociation stimulator-like 1
Aliases RGL; ralGDS-like 1
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RGL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6870.0241
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6350.648
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7260.485
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1020.722
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1190.95
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.380.873
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1440.748
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0430.979
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2930.87
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6040.657
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0280.61
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0330.765
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RGL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRGL1
Nameral guanine nucleotide dissociation stimulator-like 1
Aliases RGL; ralGDS-like 1
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RGL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRGL1
Nameral guanine nucleotide dissociation stimulator-like 1
Aliases RGL; ralGDS-like 1
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RGL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RGL1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRGL1
Nameral guanine nucleotide dissociation stimulator-like 1
Aliases RGL; ralGDS-like 1
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RGL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRGL1
Nameral guanine nucleotide dissociation stimulator-like 1
Aliases RGL; ralGDS-like 1
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RGL1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRGL1
Nameral guanine nucleotide dissociation stimulator-like 1
Aliases RGL; ralGDS-like 1
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RGL1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRGL1
Nameral guanine nucleotide dissociation stimulator-like 1
Aliases RGL; ralGDS-like 1
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RGL1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.